Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;8(6):414-22.
doi: 10.1159/000357535.

Genomic profiling in luminal breast cancer

Oleg Gluz  1 , Daniel Hofmann  1 , Rachel Würstlein  2 , Cornelia Liedtke  3 , Ulrike Nitz  1 , Nadia Harbeck  2
Affiliations
Review

Genomic profiling in luminal breast cancer

Oleg Gluz et al. Breast Care (Basel). 2013 Dec.

Abstract
in English, German

The developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.

Fortschritte bei Genexpressionsanalysen erlauben eine Einteilung des Hormonrezeptor-positiven (luminalen) Mammakarzinoms in verschiedene prognostische Untergruppen. Diese Subklassifikation wird in der klinischen Routine als prognostische Gensignatur (z.B. 21 Gene/Oncotype DX®, 70 Gene/Mammaprint®) genutzt. Die optimale Methode zur Sub-Klassifizierung ist jedoch noch nicht definiert. Bisher fehlt die Evidenz prospektiver Studien. Diese Übersichtsarbeit analysiert die am weitesten verbreiteten genomischen Signaturen im Sinne einer kritischen Bestandsaufnahme der aus retrospektiven/prospektiven Studien verfügbaren Evidenz. Diese Analyse basiert auf einer systematischen Literaturrecherche mittels Medline, sowie der bis September 2013 veröffentlichten Abstracts beim Annual Meeting of American Society of Clinical Oncology und San Antonio Breast Cancer Symposium.

Keywords: Biomarker; Breast cancer; Gene expression; Luminal breast cancer; Prognostic markers.

PubMed Disclaimer

References

    1. Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–816. - PMC - PubMed
    1. Baselga J, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366:520–529. - PMC - PubMed
    1. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747. - PubMed
    1. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874. - PMC - PubMed
    1. Mackay A, et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst. 2011;103:662–673. - PMC - PubMed